tetano
Editor, Senior Moderator
Vaccine. 2019 Aug 6. pii: S0264-410X(19)31015-1. doi: 10.1016/j.vaccine.2019.07.094. [Epub ahead of print]
[h=1]Subunit vaccines based on recombinant yeast protect against influenza A virus in a one-shot vaccination scheme.[/h] Gebauer M[SUP]1[/SUP], H?rlimann HC[SUP]2[/SUP], Behrens M[SUP]1[/SUP], Wolff T[SUP]3[/SUP], Behrens SE[SUP]4[/SUP].
[h=3]Author information[/h] 1 Martin Luther University Halle-Wittenberg, Faculty of Life Sciences (NFI), Institute of Biochemistry and Biotechnology, Kurt-Mothes-Str. 3, 06120 Halle (Saale), Germany. 2 Martin Luther University Halle-Wittenberg, Faculty of Life Sciences (NFI), Institute of Biology, Weinbergweg 10, 06120 Halle (Saale), Germany. 3 Robert Koch Institute, Unit 17 "Influenza and Other Respiratory Viruses", Seestr. 10, 13353 Berlin, Germany. 4 Martin Luther University Halle-Wittenberg, Faculty of Life Sciences (NFI), Institute of Biochemistry and Biotechnology, Kurt-Mothes-Str. 3, 06120 Halle (Saale), Germany. Electronic address: sven.behrens@biochemtech.uni-halle.de.
[h=3]Abstract[/h] Here we report on new subunit vaccines based on recombinant yeast of the type Kluyveromyces lactis (K. lactis), which protect mice from a lethal influenza A virus infection. Applying a genetic system that enables the rapid generation of transgenic yeast, we have developed K. lactis strains that express the influenza A virus hemagglutinin, HA, either individually or in combination with the viral M1 matrix protein. Subcutaneous application of the inactivated, but otherwise non-processed yeast material shows a complete protection of BALB/c mice in prime/boost and even one-shot/single dose vaccination schemes against a subsequent, lethal challenge with the cognate influenza virus. The yeast vaccines induce titers of neutralizing antibodies that are readily comparable to those induced by an inactivated virus vaccine. These data suggest that HA and M1 are produced with a high antigenicity in the yeast cells. Based on these findings, multivalent, DIVA-capable, yeast-based subunit vaccines may be developed as promising alternatives to conventional virus-based anti-flu vaccines for veterinary applications.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] DIVA; HA; Influenza; Kluveromyces lactis; M1; Subunit vaccine; Yeast vaccine
PMID: 31399274 DOI: 10.1016/j.vaccine.2019.07.094
[h=1]Subunit vaccines based on recombinant yeast protect against influenza A virus in a one-shot vaccination scheme.[/h] Gebauer M[SUP]1[/SUP], H?rlimann HC[SUP]2[/SUP], Behrens M[SUP]1[/SUP], Wolff T[SUP]3[/SUP], Behrens SE[SUP]4[/SUP].
[h=3]Author information[/h] 1 Martin Luther University Halle-Wittenberg, Faculty of Life Sciences (NFI), Institute of Biochemistry and Biotechnology, Kurt-Mothes-Str. 3, 06120 Halle (Saale), Germany. 2 Martin Luther University Halle-Wittenberg, Faculty of Life Sciences (NFI), Institute of Biology, Weinbergweg 10, 06120 Halle (Saale), Germany. 3 Robert Koch Institute, Unit 17 "Influenza and Other Respiratory Viruses", Seestr. 10, 13353 Berlin, Germany. 4 Martin Luther University Halle-Wittenberg, Faculty of Life Sciences (NFI), Institute of Biochemistry and Biotechnology, Kurt-Mothes-Str. 3, 06120 Halle (Saale), Germany. Electronic address: sven.behrens@biochemtech.uni-halle.de.
[h=3]Abstract[/h] Here we report on new subunit vaccines based on recombinant yeast of the type Kluyveromyces lactis (K. lactis), which protect mice from a lethal influenza A virus infection. Applying a genetic system that enables the rapid generation of transgenic yeast, we have developed K. lactis strains that express the influenza A virus hemagglutinin, HA, either individually or in combination with the viral M1 matrix protein. Subcutaneous application of the inactivated, but otherwise non-processed yeast material shows a complete protection of BALB/c mice in prime/boost and even one-shot/single dose vaccination schemes against a subsequent, lethal challenge with the cognate influenza virus. The yeast vaccines induce titers of neutralizing antibodies that are readily comparable to those induced by an inactivated virus vaccine. These data suggest that HA and M1 are produced with a high antigenicity in the yeast cells. Based on these findings, multivalent, DIVA-capable, yeast-based subunit vaccines may be developed as promising alternatives to conventional virus-based anti-flu vaccines for veterinary applications.
Copyright ? 2019. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] DIVA; HA; Influenza; Kluveromyces lactis; M1; Subunit vaccine; Yeast vaccine
PMID: 31399274 DOI: 10.1016/j.vaccine.2019.07.094